Work

Salvage Therapy for Aspergillosis

Year: 2005

Type: article

Abstract: Participants at the John E. Bennett Forum on Design of Clinical Trials for Fungal Infections suggested guidelines for the regulatory approval of drugs solely on the basis of salvage therapy--that is, the use of an unlicensed drug to treat patients who have experienced failure with or who have been intolerant of an approved drug. The topics covered included requirements for study design (i.e., the design allows the comparison of comparable items), entry criteria (in particular, the duration of therapy before salvage therapy is introduced), and outcome criteria that determine whether or not the treatment was successful.

Source: Clinical Infectious Diseases

DOI: 10.1086/430921

Author: John E. Bennett

Institutions: National Institutes of Health, National Institute of Allergy and Infectious Diseases

Language: English

Topic: Antifungal resistance and susceptibility

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,763